The role of tumor necrosis factor-like weak inducer of apoptosis in atherosclerosis via its two different receptors (Review)
- Authors:
- Hengdao Liu
- Dan Lin
- Hong Xiang
- Wei Chen
- Shaoli Zhao
- Hui Peng
- Jie Yang
- Pan Chen
- Shuhua Chen
- Hongwei Lu
-
Affiliations: Center for Experimental Medical Research, The Third Xiangya Hospital of Central South University, Changsha, Hunan 410013, P.R. China, Qingdao Center for Disease Control and Prevention, Qingdao, Shandong 266033, P.R. China - Published online on: June 14, 2017 https://doi.org/10.3892/etm.2017.4600
- Pages: 891-897
This article is mentioned in:
Abstract
Linden F, Domschke G, Erbel C, Akhavanpoor M, Katus HA and Gleissner CA: Inflammatory therapeutic targets in coronary atherosclerosis-from molecular biology to clinical application. Front Physiol. 5:4552014. View Article : Google Scholar : PubMed/NCBI | |
Scott J: The pathogenesis of atherosclerosis and new opportunities for treatment and prevention. J Neural Transm Suppl. 1–17. 2002.PubMed/NCBI | |
Tedgui A and Mallat Z: Cytokines in atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev. 86:515–581. 2006. View Article : Google Scholar : PubMed/NCBI | |
Blanco-Colio LM, Martin-Ventura JL, Carrero JJ, Yilmaz MI, Moreno JA, Gómez-Guerrero C, Ortiz A and Egido J: Vascular proteomics and the discovery process of clinical biomarkers: The case of TWEAK. Proteomics Clin Appl. 5:281–288. 2011. View Article : Google Scholar : PubMed/NCBI | |
Jelic-Ivanović Z, Bujisić N, Spasić S, Bogavac-Stanojević N, Spasojević-Kalimanovska V and Kotur-Stevuljević J: Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem. 42:1381–1386. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M and Fasshauer M: Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis. 199:440–444. 2008. View Article : Google Scholar : PubMed/NCBI | |
Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O and Egido J: Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol. 27:916–922. 2007. View Article : Google Scholar : PubMed/NCBI | |
Munoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J and Blanco-Colio LM: Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol. 29:2061–2068. 2009. View Article : Google Scholar : PubMed/NCBI | |
Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I and Browning JL: TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem. 272:32401–32410. 1997. View Article : Google Scholar : PubMed/NCBI | |
Bodmer JL, Schneider P and Tschopp J: The molecular architecture of the TNF superfamily. Trends Biochem Sci. 27:19–26. 2002. View Article : Google Scholar : PubMed/NCBI | |
Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA and Fanslow WC: A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity. 15:837–846. 2001. View Article : Google Scholar : PubMed/NCBI | |
Madrigal-Matute J, Fernandez-Laso V, Sastre C, Llamas-Granda P, Egido J, Martin-Ventura JL, Zalba G and Blanco-Colio LM: TWEAK/Fn14 interaction promotes oxidative stress through NADPH oxidase activation in macrophages. Cardiovasc Res. 108:139–147. 2015. View Article : Google Scholar : PubMed/NCBI | |
Moreno JA, Sastre C, Madrigal-Matute J, Muñoz-García B, Ortega L, Burkly LC, Egido J, Martín-Ventura JL and Blanco-Colio LM: HMGB1 expression and secretion are increased via TWEAK-Fn14 interaction in atherosclerotic plaques and cultured monocytes. Arterioscler Thromb Vasc Biol. 33:612–620. 2013. View Article : Google Scholar : PubMed/NCBI | |
Muñoz-Garcia B, Madrigal-Matute J, Moreno JA, Martin-Ventura JL, López-Franco O, Sastre C, Ortega L, Burkly LC, Egido J and Blanco-Colio LM: TWEAK-Fn14 interaction enhances plasminogen activator inhibitor 1 and tissue factor expression in atherosclerotic plaques and in cultured vascular smooth muscle cells. Cardiovasc Res. 89:225–233. 2011. View Article : Google Scholar : PubMed/NCBI | |
Blanco-Colio LM, Martín-Ventura JL, Munoz-Garcia B, Moreno JA, Meilhac O, Ortiz A and Egido J: TWEAK and Fn14. New players in the pathogenesis of atherosclerosis. Front Biosci. 12:3648–3655. 2007. View Article : Google Scholar : PubMed/NCBI | |
Nakayama M, Harada N, Okumura K and Yagita H: Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun. 306:819–825. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wiley SR and Winkles JA: TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev. 14:241–249. 2003. View Article : Google Scholar : PubMed/NCBI | |
Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W and Pasqualini R: A previously unrecognized protein-protein interaction between TWEAK and CD163: Potential biological implications. J Immunol. 178:8183–8194. 2007. View Article : Google Scholar : PubMed/NCBI | |
Ilter A, Orem C, Yucesan F Balaban, Sahin M, Hosoglu Y, Kurumahmutoglu E, Yaman S Ozer and Orem A: Evaluation of serum sTWEAK and sCD163 levels in patients with acute and chronic coronary artery disease. Int J Clin Exp Med. 8:9394–9402. 2015.PubMed/NCBI | |
Valdivielso JM, Coll B, Martin-Ventura JL, Moreno JA, Egido J, Fernández E and Blanco-Colio LM: Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol Nephrol Nephrol. 26:1105–1113. 2013. | |
Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J and Blanco-Colio LM: The CD163-expressing macrophages recognize and internalize TWEAK Potential consequences in atherosclerosis. Atherosclerosis. 207:103–110. 2009. View Article : Google Scholar : PubMed/NCBI | |
Feng SL, Guo Y, Factor VM, Thorgeirsson SS, Bell DW, Testa JR, Peifley KA and Winkles JA: The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol. 156:1253–1261. 2000. View Article : Google Scholar : PubMed/NCBI | |
Meighan-Mantha RL, Hsu DK, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, et al: The mitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem. 274:33166–33176. 1999. View Article : Google Scholar : PubMed/NCBI | |
Brown SA, Richards CM, Hanscom HN, Feng SL and Winkles JA: The Fn14 cytoplasmic tail binds tumour-necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem J. 371:395–403. 2003. View Article : Google Scholar : PubMed/NCBI | |
Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N and Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 278:36005–36012. 2003. View Article : Google Scholar : PubMed/NCBI | |
Blanco-Colio LM: TWEAK/Fn14 Axis: A promising target for the treatment of cardiovascular diseases. Front Immunol. 5:32014. View Article : Google Scholar : PubMed/NCBI | |
Felli N, Pedini F, Zeuner A, Petrucci E, Testa U, Conticello C, Biffoni M, Di Cataldo A, Winkles JA, Peschle C and De Maria R: Multiple members of the TNF superfamily contribute to IFN-gamma-mediated inhibition of erythropoiesis. J Immunol. 175:1464–1472. 2005. View Article : Google Scholar : PubMed/NCBI | |
Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS and Burkly LC: Dual role for TWEAK in angiogenic regulation. J Cell Sci. 115:267–274. 2002.PubMed/NCBI | |
Justo P, Sanz AB, Sanchez-Niño MD, Winkles JA, Lorz C, Egido J and Ortiz A: Cytokine cooperation in renal tubular cell injury: The role of TWEAK. Kidney Int. 70:1750–1758. 2006. View Article : Google Scholar : PubMed/NCBI | |
Munoz-García B, Martin-Ventura JL, Martínez E, Sánchez S, Hernández G, Ortega L, Ortiz A, Egido J and Blanco-Colio LM: Fn14 is upregulated in cytokine-stimulated vascular smooth muscle cells and is expressed in human carotid atherosclerotic plaques: Modulation by atorvastatin. Stroke. 37:2044–2053. 2006. View Article : Google Scholar : PubMed/NCBI | |
Tuttolomondo A, Di Raimondo D, Pecoraro R, Arnao V, Pinto A and Licata G: Atherosclerosis as an inflammatory disease. Curr Pharm Des. 18:4266–4288. 2012. View Article : Google Scholar : PubMed/NCBI | |
Weissberg PL and Bennett MR: Atherosclerosis-an inflammatory disease. N Engl J Med. 340:1928–1929. 1999. View Article : Google Scholar : PubMed/NCBI | |
Gimbrone MA Jr and Garcia-Cardeña G: Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis. Cardiovasc Pathol. 22:9–15. 2013. View Article : Google Scholar : PubMed/NCBI | |
Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H and Okumura K: Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun. 299:488–493. 2002. View Article : Google Scholar : PubMed/NCBI | |
Shi N and Chen SY: Mechanisms simultaneously regulate smooth muscle proliferation and differentiation. J Biomed Res. 28:40–46. 2014.PubMed/NCBI | |
Chistiakov DA, Orekhov AN and Bobryshev YV: Vascular smooth muscle cell in atherosclerosis. Acta Physiol (Oxf). 214:33–50. 2015. View Article : Google Scholar : PubMed/NCBI | |
Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA and Wiley SR: TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem. 274:8455–8459. 1999. View Article : Google Scholar : PubMed/NCBI | |
Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, Hwang K and Lee S Young: TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NF-kappa B through TNF receptor-associated factors. Biochem Biophys Res Commun. 305:789–796. 2003. View Article : Google Scholar : PubMed/NCBI | |
Mackman N: Role of tissue factor in hemostasis and thrombosis. Blood Cells Mol Dis. 36:104–107. 2006. View Article : Google Scholar : PubMed/NCBI | |
Potempa J, Korzus E and Travis J: The serpin superfamily of proteinase inhibitors: Structure, function, and regulation. J Biol Chem. 269:15957–15960. 1994.PubMed/NCBI | |
Schecter AD, Spirn B, Rossikhina M, Giesen PL, Bogdanov V, Fallon JT, Fisher EA, Schnapp LM, Nemerson Y and Taubman MB: Release of active tissue factor by human arterial smooth muscle cells. Circ Res. 87:126–132. 2000. View Article : Google Scholar : PubMed/NCBI | |
Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F and Kruithof EK: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 13:1090–1100. 1993. View Article : Google Scholar : PubMed/NCBI | |
Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD and Nemerson Y: Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 78:200–204. 1997.PubMed/NCBI | |
Agirbasli M: Pivotal role of plasminogen-activator inhibitor 1 in vascular disease. Int J Clin Pract. 59:102–106. 2005. View Article : Google Scholar : PubMed/NCBI | |
Spinas E, Kritas SK, Saggini A, Mobili A, Caraffa A, Antinolfi P, Pantalone A, Tei M, Speziali A, Saggini R and Conti P: Role of mast cells in atherosclerosis: A classical inflammatory disease. Int J Immunopathol Pharmacol. 27:517–521. 2014. View Article : Google Scholar : PubMed/NCBI | |
Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol. 21:1876–1890. 2001. View Article : Google Scholar : PubMed/NCBI | |
Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, Kockx MM, Daemen MJ and Heeneman S: Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/-mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol. 29:2021–2027. 2009. View Article : Google Scholar : PubMed/NCBI | |
Kim SH, Kang YJ, Kim WJ, Woo DK, Lee Y, Kim DI, Park YB, Kwon BS, Park JE and Lee WH: TWEAK can induce pro-inflammatory cytokines and matrix metalloproteinase-9 in macrophages. Circ J. 68:396–399. 2004. View Article : Google Scholar : PubMed/NCBI | |
Sastre C, Fernández-Laso V, Madrigal-Matute J, Muñoz-García B, Moreno JA, Pastor-Vargas C, Llamas-Granda P, Burkly LC, Egido J, Martín-Ventura JL and Blanco-Colio LM: Genetic deletion or TWEAK blocking antibody administration reduce atherosclerosis and enhance plaque stability in mice. J Cell Mol Med Med Cell Mol Med. 18:721–734. 2014. View Article : Google Scholar | |
Madamanchi NR and Runge MS: Mitochondrial dysfunction in atherosclerosis. Circ Res. 100:460–473. 2007. View Article : Google Scholar : PubMed/NCBI | |
Munzel T, Gori T, Bruno RM and Taddei S: Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 31:2741–2748. 2010. View Article : Google Scholar : PubMed/NCBI | |
Scaffidi P, Misteli T and Bianchi ME: Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI | |
Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, Ilyinskaya O, Tararak E and Bobik A: Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: Role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol. 24:2320–2325. 2004. View Article : Google Scholar : PubMed/NCBI | |
Andersson U, Erlandsson-Harris H, Yang H and Tracey KJ: HMGB1 as a DNA-binding cytokine. J Leukoc Biol. 72:1084–1091. 2002.PubMed/NCBI | |
Inoue K, Kawahara K, Biswas KK, Ando K, Mitsudo K, Nobuyoshi M and Maruyama I: HMGB1 expression by activated vascular smooth muscle cells in advanced human atherosclerosis plaques. Cardiovasc Patho. 16:136–143. 2007. View Article : Google Scholar | |
Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK and Moestrup SK: Identification of the haemoglobin scavenger receptor. Nature. 409:198–201. 2001. View Article : Google Scholar : PubMed/NCBI | |
Jasiewicz M, Kowal K, Kowal-Bielecka O, Knapp M, Skiepko R, Bodzenta-Lukaszyk A, Sobkowicz B, Musial WJ and Kaminski KA: Serum levels of CD163 and TWEAK in patients with pulmonary arterial hypertension. Cytokine. 66:40–45. 2014. View Article : Google Scholar : PubMed/NCBI | |
Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J and Blanco-Colio LM: Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis. 219:892–899. 2011. View Article : Google Scholar : PubMed/NCBI | |
Beltran LM, Muñoz Hernández R, de Pablo Bernal RS, García Morillo JS, Egido J, Noval ML, Ferrando-Martinez S, Blanco-Colio LM, Genebat M, Villar JR, et al: Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: Modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One. 9:e905412014. View Article : Google Scholar : PubMed/NCBI | |
Llauradó G, González-Clemente JM, Maymó-Masip E, Subías D, Vendrell J and Chacón MR: Serum levels of TWEAK and scavenger receptor CD163 in type 1 diabetes mellitus: Relationship with cardiovascular risk factors. A case-control study. PLoS One. 7:e439192012. View Article : Google Scholar : PubMed/NCBI | |
Van Gorp H, Delputte PL and Nauwynck HJ: Scavenger receptor CD163, a Jack-of-all-trades and potential target for cell-directed therapy. Mol Immunol. 47:1650–1660. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kowal K, Silver R, Sławińska E, Bielecki M, Chyczewski L and Kowal-Bielecka O: CD163 and its role in inflammation. Folia Histochem Cytobiol. 49:365–374. 2011. View Article : Google Scholar : PubMed/NCBI | |
Moller HJ, Nielsen MJ, Maniecki MB, Madsen M and Moestrup SK: Soluble macrophage-derived CD163: A homogenous ectodomain protein with a dissociable haptoglobin-hemoglobin binding. Immunobiology. 215:406–412. 2010. View Article : Google Scholar : PubMed/NCBI | |
Etzerodt A and Moestrup SK: CD163 and inflammation: Biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal. 18:2352–2363. 2013. View Article : Google Scholar : PubMed/NCBI | |
Backe E, Schwarting R, Gerdes J, Ernst M and Stein H: Ber-MAC3: New monoclonal antibody that defines human monocyte/macrophage differentiation antigen. J Clin Pathol. 44:936–945. 1991. View Article : Google Scholar : PubMed/NCBI | |
Chamorro S, Revilla C, Alvarez B, Alonso F, Ezquerra A and Domínguez J: Phenotypic and functional heterogeneity of porcine blood monocytes and its relation with maturation. Immunology. 114:63–71. 2005. View Article : Google Scholar : PubMed/NCBI | |
Baeten D, Møller HJ, Delanghe J, Veys EM, Moestrup SK and De Keyser F: Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis. Arthritis Rheum. 50:1611–1623. 2004. View Article : Google Scholar : PubMed/NCBI | |
Bronkhorst IH, Ly LV, Jordanova ES, Vrolijk J, Versluis M, Luyten GP and Jager MJ: Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci. 52:643–650. 2011. View Article : Google Scholar : PubMed/NCBI | |
Ratcliffe NR, Kennedy SM and Morganelli PM: Immunocytochemical detection of Fcgamma receptors in human atherosclerotic lesions. Immunol Lett. 77:169–174. 2001. View Article : Google Scholar : PubMed/NCBI | |
Högger P, Dreier J, Droste A, Buck F and Sorg C: Identification of the integral membrane protein RM3/1 on human monocytes as a glucocorticoid-inducible member of the scavenger receptor cysteine-rich family (CD163). J Immunol. 161:1883–1890. 1998.PubMed/NCBI | |
Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM and Guyre PM: Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine. 12:1312–1321. 2000. View Article : Google Scholar : PubMed/NCBI | |
Timmermann M and Högger P: Oxidative stress and 8-iso-prostaglandin F(2alpha) induce ectodomain shedding of CD163 and release of tumor necrosis factor-alpha from human monocytes. Free Radic Biol Med. 39:98–107. 2005. View Article : Google Scholar : PubMed/NCBI | |
Zwadlo G, Voegeli R, Osthoff K Schulze and Sorg C: A monoclonal antibody to a novel differentiation antigen on human macrophages associated with the down-regulatory phase of the inflammatory process. Exp Cell Biol. 55:295–304. 1987.PubMed/NCBI | |
Buechler C, Ritter M, Orsó E, Langmann T, Klucken J and Schmitz G: Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 67:97–103. 2000.PubMed/NCBI | |
Van den Heuvel MM, Tensen CP, van As JH, Van den Berg TK, Fluitsma DM, Dijkstra CD, Döpp EA, Droste A, Van Gaalen FA, Sorg C, et al: Regulation of CD 163 on human macrophages: Cross-linking of CD163 induces signaling and activation. J Leukoc Biol. 66:858–866. 1999.PubMed/NCBI | |
Schaer DJ, Boretti FS, Schoedon G and Schaffner A: Induction of the CD163-dependent haemoglobin uptake by macrophages as a novel anti-inflammatory action of glucocorticoids. Br J Haematol. 119:239–243. 2002. View Article : Google Scholar : PubMed/NCBI | |
Varga G, Ehrchen J, Tsianakas A, Tenbrock K, Rattenholl A, Seeliger S, Mack M, Roth J and Sunderkoetter C: Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol. 84:644–650. 2008. View Article : Google Scholar : PubMed/NCBI | |
Hogger P, Erpenstein U, Rohdewald P and Sorg C: Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res. 15:296–302. 1998. View Article : Google Scholar : PubMed/NCBI | |
Weaver LK, Pioli PA, Wardwell K, Vogel SN and Guyre PM: Up-regulation of human monocyte CD163 upon activation of cell-surface Toll-like receptors. J Leukoc Biol. 81:663–671. 2007. View Article : Google Scholar : PubMed/NCBI | |
Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP and Guyre PM: Endotoxin induces rapid metalloproteinase-mediated shedding followed by up-regulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 72:711–717. 2002.PubMed/NCBI | |
Gleissner CA, Shaked I, Erbel C, Böckler D, Katus HA and Ley K: CXCL4 downregulates the atheroprotective hemoglobin receptor CD163 in human macrophages. Circ Res. 106:203–211. 2010. View Article : Google Scholar : PubMed/NCBI | |
Levy AP and Moreno PR: Intraplaque hemorrhage. Curr Mol Med. 6:479–488. 2006. View Article : Google Scholar : PubMed/NCBI | |
Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP and Narula J: Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol. 25:2054–2061. 2005. View Article : Google Scholar : PubMed/NCBI | |
Schaer DJ and Buehler PW: Cell-free hemoglobin and its scavenger proteins: New disease models leading the way to targeted therapies. Cold Spring Harb Perspect Med. 3(pii): a0134332013.PubMed/NCBI | |
Madsen M, Møller HJ, Nielsen MJ, Jacobsen C, Graversen JH, van den Berg T and Moestrup SK: Molecular characterization of the haptoglobin.hemoglobin receptor CD163. Ligand binding properties of the scavenger receptor cysteine-rich domain region. J Biol Chem. 279:51561–51567. 2004. View Article : Google Scholar : PubMed/NCBI | |
Schaer CA, Schoedon G, Imhof A, Kurrer MO and Schaer DJ: Constitutive endocytosis of CD163 mediates hemoglobin-heme uptake and determines the noninflammatory and protective transcriptional response of macrophages to hemoglobin. Circ Res. 99:943–950. 2006. View Article : Google Scholar : PubMed/NCBI | |
Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO and Landis RC: Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res. 94:119–126. 2004. View Article : Google Scholar : PubMed/NCBI | |
Nielsen MJ, Møller HJ and Moestrup SK: Hemoglobin and heme scavenger receptors. Antioxid Redox Signal. 12:261–273. 2010. View Article : Google Scholar : PubMed/NCBI | |
Polek TC, Talpaz M, Darnay BG and Spivak-Kroizman T: TWEAK mediates signal transduction and differentiation of RAW264.7 cells in the absence of Fn14/TweakR. Evidence for a second TWEAK receptor. J Biol Chem. 278:32317–32323. 2003. View Article : Google Scholar : PubMed/NCBI | |
Burkly LC, Michaelson JS, Hahm K, Jakubowski A and Zheng TS: TWEAKing tissue remodeling by a multifunctional cytokine: Role of TWEAK/Fn14 pathway in health and disease. Cytokine. 40:1–16. 2007. View Article : Google Scholar : PubMed/NCBI | |
Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, et al: Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol. 30:1253–1262. 2010. View Article : Google Scholar : PubMed/NCBI | |
Kowal-Bielecka O, Bielecki M, Guiducci S, Trzcinska-Butkiewicz B, Michalska-Jakubus M, Matucci-Cerinic M, Brzosko M, Krasowska D, Chyczewski L and Kowal K: High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis. Arthritis Res Ther. 15:R692013. View Article : Google Scholar : PubMed/NCBI | |
Møller HJ: Soluble CD163. Scand J Clin Lab Invest. 72:1–13. 2012. View Article : Google Scholar : PubMed/NCBI | |
Goldstein JL and Brown MS: Regulation of the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI |